Anaptysbio (ANAB) Cash from Investing Activities (2016 - 2026)

Anaptysbio (ANAB) has 11 years of Cash from Investing Activities data on file, last reported at $35.0 million in Q1 2026.

• Quarterly Cash from Investing Activities rose 135.62% year-over-year to $35.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $248.2 million (up 496.14% YoY) and the FY2025 annual result came in at $228.0 million, up 139.03% from the prior year.
• Cash from Investing Activities fell to $35.0 million in Q1 2026, from $73.5 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $103.3 million in Q3 2025 to a low of -$312.9 million in Q1 2022.
• A 5-year average of $6.4 million and a median of $30.6 million in 2023 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities plunged 651.59% — and 2025, when it surged 1590.7%.
• Tracing ANAB's Cash from Investing Activities over 5 years: stood at $21.5 million in 2022, then surged by 128.77% to $49.2 million in 2023, then tumbled by 159.77% to -$29.4 million in 2024, then jumped by 350.03% to $73.5 million in 2025, then slumped by 52.4% to $35.0 million in 2026.
• The last three Cash from Investing Activities figures came in at $35.0 million (Q1 2026), $73.5 million (Q4 2025), and $103.3 million (Q3 2025), per Business Quant data.